We see health care. differently. Comprehensive data Novel insights Transformative actions Lasting value
|
|
- Joseph Warren
- 6 years ago
- Views:
Transcription
1 We see health care differently Comprehensive data Novel insights Transformative actions Lasting value
2 24 Hours of Optum data: Creating a more complete health picture We capture: Largest EHR dataset 90 million lives Largest eligibilitycontrolled claims dataset 160 million lives $749M Health care costs 4.8M Diagnoses 8.3M Signs, diseases, symptoms (provider notes) 4.0M Procedures 2.8M Measurements (provider notes) 1.9M Medications prescribed, administered and filled 4.9M Vital signs and observations 3.2M Lab results More than 150,000 providers 2,000 hospitals 7,000 clinics Only person-linked, integrated dataset 30 million EHR linked Rx claims 2
3 The funnel challenge: What business questions do you need to answer? Quality data manufacturing leads to more useable, research-ready patients Competitor data Optum data Data usability is a function of patients meeting research requirements such as clinical markers of interest and tenure Usable patients Usable patients 3
4 How did we get here? 4
5 Dyslipidemia Case Study
6 Quantifying Statin Intolerance A common reason for statin-related sides effects is Statin Associated Muscle Symptoms (SAMS). In our study, these qualitative symptoms were limited to: muscle aches, muscle weakness, muscle stiffness, muscle cramps, myalgias, and myositis. Approximately 90% of all statin-related side effects occur within the 1 st 6 months after initiation of therapy. We define statin intolerance as a patient reporting these symptoms within 1 year after initiation of a statin therapy. Description Patients # Patients Taking a Statin 6,929,680 # Patients Experiencing SAMS 1,951,936 % Patients Experiencing SAMS 28.2% # Patients Experiencing SAMS with No Preexisting History 924,519 Estimated % With Statin Intolerance 13.3% Patients Receive PCSK9 2,111 Patients Receiving PCSK9 After Statin Intolerance 900 American Heart Association s Estimate = 10-15% Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 6
7 Quantifying Statin Intolerance A common reason for statin-related sides effects is Statin Associated Muscle Symptoms (SAMS). In our study, these qualitative symptoms were limited to: muscle aches, muscle weakness, muscle stiffness, muscle cramps, myalgias, and myositis. Approximately 90% of all statin-related side effects occur within the 1 st 6 months after initiation of therapy. We define statin intolerance as a patient reporting these symptoms within 1 year after initiation of a statin therapy. Description Patients # Patients Taking a Statin 6,929,680 # Patients Experiencing SAMS 1,951,936 % Patients Experiencing SAMS 28.2% # Patients Experiencing SAMS with No Preexisting History 924,519 Estimated % With Statin Intolerance 13.3% Patients Receive PCSK9 2,111 Patients Receiving PCSK9 After Statin Intolerance 900 American Heart Association s Estimate = 10-15% Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 7
8 Statin Intolerance Symptoms by Number of Statins For patients who did not have symptoms within 1 year before starting a statin, the graph below shows the number of patients with statin intolerance symptoms looking 1 year after being prescribed/administered the medication ~1/5 of patients already complain of symptoms despite being on only 1 statin, and these symptoms increase as the patient is prescribed different statins By the time patients try 3 or more statins, almost 40% of the patients show statin intolerance symptoms within 1 year 1 Statin 2 Statins 3+ Statins Patients with Statin Intolerance Symptoms from Physician Notes 1M 2M 3M 4M 5M Only a small proportion (<1%) of patients with symptoms are then prescribed a PCSK9 850 (0.1%) 705 (0.2%) 555 (0.5%) Patients without Symptom Mentions Patients with Statin Intolerance Symptom Mentions Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 8
9 Days Between Statin Intolerance and PCKS9 Prescription Days Between Statin Intolerance and Prescription for a PCSK9 It takes > 180 days for many patients to receive a PCSK9 after they are defined as statin intolerant. Using the integrated data, one could calculate the cardiovascular related costs for the long and short patients, and if the long patients incur greater costs, an argument could be made that PCSK9s should be prescribed earlier in the treatment pathway Early Patients Late Patients Patients With a PSCK9 Prescription After Statin Intolerance Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 9
10 Optum solved one of the biggest problems in health care: Multiple EMR systems that do not communicate with one another Multi-specialty practices EMR1 Rx platform Billing system Small group practices EMR2 Rx platform Billing system Medical groups Physician offices EMR 3 Rx platform Billing system Integrated delivery networks EMR1 EMR2 Rx platform Billing system Hospitals EMR3 Staging area Provider notes Demographics Lab results Procedures (NLP) Diagnosis Medications Outpatient visits Vital signs Hospitalizations Observations Processing: Validation, normalization, standardization, mapping Analytics for providers Longitudinal comprehensive clinical dataset Data and analytics for life sciences 10
11 Optum s Cohort Builder quickly defines and profiles study populations, simplifying and speeding time to analysis, insight and evidence generation 11
12 The Cost of Hypoglycemia 12
13 Understanding Impact of Hypoglycemia WITHOUT Hypoglycemic Events COST WITH Hypoglycemic Events COST Pharmacy (AWP) $27.77 PMPM Medical (Std. Cost) $1, PMPM Pharmacy (AWP) $9.17 PMPM Medical (Std. Cost) $4, PMPM Confidential property of Optum. Do not distribute or reproduce without express permission from Optum.
14 DIABETES WITHOUT HYPOGLYCEMIC EVENT DIABETES WITH HYPOGLYCEMIC EVENT Event of Interest: Diabetes diagnosis Event of Interest: Hypoglycemic event Confidential property of Optum. Do not distribute or reproduce without express permission from Optum.
15 Comprehensive data leads to novel insights for brand marketing, value-based contracting, comparative effectives and evidence generation Provider notes Treatment rationale, lifestyle observations, signs and symptoms, biomarkers Medications Therapeutic-area-specific market baskets Vital signs BMI, blood pressure, pain scores Cost Disease burden for pharmacy, provider, and facility spend Claims 120M+ Linked EHR/ claims: 15M+ EHR 80M+ Lab values More than 260 different labs (e.g., A1C, egfr, FEV, values) Medical procedures and conditions Indications, treatments and comorbidities Patient and provider details Physician speciality, age, gender, smoking status, race geography 15
16 Holistic view, informed by data and illuminated by tools, guides actions and creates common understanding of value Holistic view of patient journey Not just what, but why: Detailed understanding of drivers of treatment choice at critical care-milestones Enables more precise understanding: who, what, when Who Patient, provider, payer What Tailored interventions: messaging, support programs and tools When At critical junctures in the patient journey Optum Patient Journey application Optimization of interventional, promotional, educational spends for patients, providers, payers 16
17 Primary Adherence 17
18 Breast Cancer Oral Medication Overview Between , the overall patients represented in the EHR linked all payor data who have a prescription for one of the medications of interest is ~33K Just over 1K patients have a prescription for Ibrance Patient Count by Medication ( ) 25,000 20,000 19,441 n = 33,120 patients 15,000 11,848 10,000 5, ,006 1,163 Arimidex Aromasin Femara Ibrance Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 18
19 % of Written Prescriptions Primary Adherence by Brand Looking at primary adherence differences between the 4 brands shows that Ibrance only has half the fill rate compared to Aromatase Inhibitors Majority of Ibrance prescriptions are not filled, whereas <40% of Aromatase Inhibitors are not filled Primary Adherence by Brand 68.0% 65.1% 60.4% 66.0% 33.6% 39.4% 34.8% 31.9% Legend Arimidex Aromasin Femara Ibrance Filled as Written 0.0% 0.1% 0.0% 0.3% 0.0% 0.1% 0.1% 0.0% Filled Another Brand Filled Another Brand (Different Class) (Same Class) Primary Adherence No Fills Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 19
20 % of Rx Claims Payment Type by Brand For medications that were filled as written, the addition of the all payor data shows variation in the type of payment Patients adhering to Ibrance are more likely to use commercial insurance and cash compared to the other payment methods for the Aromatase Inhibitors 46.9% 44.9% 40.8% 41.5% Payment Type by Product 37.7% 36.4% 16.0% 1.3% 2.4% 0.9% 0.0% 0.0% 0.1% 0.0% 6.0% 2.8% 2.8% 2.8% 27.0% 22.1% Legend Arimidex Aromasin Femara Ibrance Cash Commercial Manufacturer Medicaid Payment program Type for Pharmacy Claim Medicare Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 20
21 % of Written Prescriptions Biomarker Status and Primary Adherence Out of patients with medications of interest and eligible for primary adherence: Prescriptions for Patients with Biomarker Status HR Positive HER2 Negative HR+/HER2-7,840 7,407 10,388 For patients with an indicated biomarker status of HR+/HER2-, the filled as written rate is increased for Ibrance, but slightly decreased for aromatase inhibitors Filled as Written vs. No Fill Rate for HR+/HER2- Patients n = 7, % 34.0% 55.5% 44.5% 62.7% 37.1% 36.1% 63.5% Filled as Written No Fills Filled as Written No Fills Filled as Written No Fills Filled as Written No Fills Arimidex Aromasin Femara Ibrance Confidential property of Optum. Do not distribute or reproduce without express permission from Optum. 21
22 Claims + EHR data expansion One of the largest and most complete claims data assets in the United States Optum insurance claims Linked EHR/ claims Optum EHR One of the largest and broadest EHR data assets in the United States More than 1 billion prescriptions per year from 76 million patients per year: 25 30% is eligibility controlled (30 million lives) Includes data from 90%+ of HCPs 90%+ of pharmacies All payers, including cash All-payer Rx claims Adding one of the largest aggregators of pharmacy claims Adding Rx claims for: 1. Individuals with EHR capture and Optum insurance claims 2. Individuals with EHR capture alone 22
23 23
24 24
25 > NEAR Expanded Offerings for Enterprise- Wide Enablement
26 A New World of Use Cases Robust and Precise Medical & Scientific Audiences Fast, Representative and Actionable Commercial and Sales Audiences P r o d u c t s Panther Smart Files CDMs Clinformatics Provider RWE Patient Journey Cohort Builder Comparative Analytics Integrated All-Payer Panther (with weekly updates) North Star Commercial Analytics F e a t u r e s Evidence Generation Data Patient-Centric Quarterly updates Full history of information: Visits Labs Meds Dx s Insight Expansion Data Moment-of-Truth based Weekly updates Most recent information: Written Filled prescription tracking Most recent lab value Dx indication for prescription Admissions & Re-admissions 26
27 The Objective of Our Data and Tools To Illuminate Three Pillars There are three main pillars of insights needed to tell the full story of which care works best and why $ $ $ $ $ SOCIAL, ENVIRONMENTAL AND BEHAVIORAL HEALTHCARE DELIVERY PAYMENT & ACCESS We combine these three perspectives to provide the most complete view of patient perspective, cost and outcomes available in the market today. 27
28 Healthcare Requires a Centralized View of the Patient, and Optum is Positioned to Construct that View Eligibility Cost PATIENT Rx fills Labs Financial strain Physician notes Devices Media exposure Vitals Diagnoses Payment and access Consumer behavior Clinical severity Procedures CPG Diagnoses Procedures Reported outcomes Written Rx User-generated information 28
29 Optum integrates data from across the health care ecosystem, enlarging and enriching our view of the patient, provider and payer Social, Environmental & Behavioral Data Socio-Demographic Health Risk Assessment Media & Digital Exposure Wearable / Device Data Patient Engagement Data Promotional Exposure Purchasing Patterns Loyalty / Membership Survey Responses SEB DATA Reported Outcomes $ CLINICAL DATA CLAIMS DATA Healthcare Delivery Data Electronic Health Records Electronic Medical Records Clinical Notes Genomic Data Registry Data Care Management Program Data Payment & Access Data Medical & Pharmacy Insurance Claims Eligibility & Enrollment Data All-Payer Pharmacy Claims Point of Sale Data Orange: In production: The largest deterministically linked Claims Electronic Health Record data asset on the market; additional data assets listed are part of Optum s expanding data eco-system 29
30 Near Term Focus $ C o n t i n u e t o b u i l d E H R - b a s e d p o p u l a t i o n E x p a n d a l l - p a y e r m e d i c a l a n d p h a r m a c y p o p u l a t i o n s D e e p e n g e n o m i c i n s i g h t s : B i o m a r k e r s T u m o r t y p i n g I n c o r p o r a t e n o v e l d a t a : C o n s u m e r D a t a W e a r a b l e D a t a P a t i e n t R e p o r t e d O u t c o m e s ( P R O ) Boost denominator and scope of insights Organic growth of EHR patients Multi-sourced EMR patients Integrated (claims + EHR) patients Increased speed at the time of prescriptions (Dx, Labs, NLPderived) Diversify payer representation Boost integrated patient counts Improve cost / utilization perspective for research Provide broad market representation of brand share / formulary choice for commercial audiences Demonstrate pharmaco-genomic interactions Oncology Auto-immune disorders Rare diseases Incorporate patient s perspective and behavior outside of the health system Front Store Pharmacy PRO s Media 30
31 Steve Davis SVP, Data and Advanced Analytic Tools 31
Sanofi Press Breakfast on Behavioral Science. Friday 22 September 2017
Sanofi Press Breakfast on Behavioral Science Friday 22 September 2017 Agenda WHY UNDERSTANDING BEHAVIORS CAN UNLOCK CARE SUCCESS 8.45-9.00 Welcome coffee 9.00 Kick-off 9.00-9.10 Introduction by Alexandra
More informationJukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:
Hospital to Retail Spillover Analysis and Its Impact on Commercial Decision Making Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at: 1 Disclaimer The information provided and
More informationBig Data & Predictive Analytics Case Studies: Applying data science to human data Big-Data.AI Summit
Big Data & Predictive Analytics Case Studies: Applying data science to human data 1.03.2018 Big-Data.AI Summit Dr. Arnim Jost, Commercial Director Technology Copyright 2017 IQVIA. All rights reserved.
More informationIn all of these roles, I've used healthcare data to drive strategy for the life sciences industry.
Intro: When you take a magnifying glass and look at a picture, you see that it's made up of thousands of dots and when you pull back, those dots become the details that create the picture. There's real
More informationTeam-Based Decision Support in Diabetes Outcomes and Costs
Team-Based Decision Support in Diabetes Outcomes and Costs Session 89, 8:30 a.m. February 13, 2019 Gary Ozanich, Ph.D. - College of Informatics, Northern Kentucky University 1 Conflict of Interest Gary
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationBringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence. March IIeX Health, Philadelphia, PA
Bringing Together Clinical, Economic and Patient Reported Outcomes Data Future Of Real World Evidence March 27 2018 IIeX Health, Philadelphia, PA Overview Current Landscape Data Sources to generate Real
More informationWatson Summit Prague 2017
Watson for Oncology Matěj Adam Watson Health Executive May 2017 Watson Summit Prague 2017 an IBM Company Leadership & 23 Years Patent Leadership Research Spend Global Presence Technology 7300+ 2015 $6B
More informationPractical Predictive Analytics. John Cuddeback, MD, PhD AMA IPPS November 11, 2016
Practical Predictive Analytics John Cuddeback, MD, PhD AMA IPPS November 11, 2016 AMGA s Work in Analytics Advocacy: Align payment incentives around population health Programs: Help members redesign delivery
More informationValue-Driven Population Health Strategies: Designing Models for Different Populations
Value-Driven Population Health Strategies: Designing Models for Different Populations Expert presenters Dan Dunn, Ph.D., SVP, Business Solutions, Distinguished Fellow, Optum Mark Leenay, M.S., M.D., Chief
More informationReal World Patients: The Intersection of Real World Evidence and Episode of Care Analytics
PharmaSUG 2018 - Paper RW-05 Real World Patients: The Intersection of Real World Evidence and Episode of Care Analytics David Olaleye and Youngjin Park, SAS Institute Inc. ABSTRACT SAS Institute recently
More informationOver 425 Members Strong
Quality Measurement 101: The Basics Camille Smith, MSW, MSPH Director, Member Education Karen Johnson, MS Senior Director, Quality Measurement October 8, 2015 2:00pm-3:00pm ET Over 425 Members Strong 2
More informationProvider Service Model. Collaborating for Success Jodi Stockslager, Sr. Provider Advocate, Provider Relations
Provider Service Model Collaborating for Success Jodi Stockslager, Sr. Provider Advocate, Provider Relations Agenda Welcome / Introductions UnitedHealthcare overview Member ID Cards Products and networks
More informationUses of the NIH Collaboratory Distributed Research Network
Uses of the NIH Collaboratory Distributed Research Network Jeffrey Brown, PhD for the DRN Team Harvard Pilgrim Care Institute and Harvard Medical School March 11, 2016 The Goal The NIH Collaboratory DRN
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationA COMPREHENSIVE APPROACH TO MANAGING DIABETES
A COMPREHENSIVE APPROACH TO MANAGING DIABETES Programs and services to help individuals avoid costly complications and improve outcomes 2 0 1 8 ENTER Supporting each member with targeted guidance and services.
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationMember-centered cancer care In Georgia
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Member-centered cancer care In Georgia Ira Klein, MD, MBA, FACP GASCO Annual Meeting September 5, 2015 > One
More informationImproving Type 2 Diabetes Therapy Adherence and Persistence in the United States
July 2016 Improving Type 2 Diabetes Therapy Adherence and Persistence in the United States Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the report entitled
More informationData-Driven Study Feasibility Assessment and Impact on Successful Execution of Clinical Trial Protocols
Data-Driven Study Feasibility Assessment and Impact on Successful Execution of Clinical Trial Protocols Bill Gwinn Vice-President Clinical Informatics Solutions Optum DIA Session: Next Generation Feasibility:
More informationData Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis
February, 13th 2018 Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies:
More informationImproving Type 2 Diabetes Therapy Compliance and Persistence in Brazil
July 2016 Improving Type 2 Diabetes Therapy Compliance and Persistence in Brazil Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the report entitled Improving
More informationNAVIFY Tumor Board NAVIFY
NAVIFY Tumor Board Make the most informed personalized treatment decisions possible by leveraging innovative technologies and the latest scientific and clinical data WHAT S INSIDE Key Takeaways NAVIFY
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationAdvancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development
Advancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development Assessing Clinical Utility with Real-World Evidence IOM/CMTP Workshop May 2012 G. Rossi Ph.D. V.P. Payer and
More informationThe Linked SEER-Medicare Data and Cancer Effectiveness Research
The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive
More informationEffective Strategies to Help Customers Use Their EHR to Improve Quality of Care
Effective Strategies to Help Customers Use Their EHR to Improve Quality of Care Brian Bamberger Life Sciences Practice Leader Technology is transforming healthcare Health technology will continue to diffuse
More information16 th Annual IHA Stakeholders Meeting Session 2C
16 th Annual IHA Stakeholders Meeting Session 2C September 19, 2017 Hilton Los Angeles Airport Thank you to our Content Partner: Medication Adherence AppleCare Pharmacy Programs Confidential and proprietary.
More informationUsing Analytics for Value-Based Care
Using Analytics for Value-Based Care John Cuddeback, MD, PhD Elizabeth Ciemins, PhD, MPH, MA AMGA Northwest Regional Meeting February 3, 2017 Seattle A Fundamental Change Is Underway Fee for Service MIPS
More informationICD-10 Implementation: From ICD-10? to I Can Do-10!
ICD-10 Implementation: From ICD-10? to I Can Do-10! Prepared For: OH Home and Community Based Service Providers August 12, 2015 Webex Presented By: Aaron R. Sapp, MPS National ICD-10 Program Director Insurance
More informationImproving Type 2 Diabetes Therapy Adherence and Persistence in Mexico
July 2016 Improving Type 2 Diabetes Therapy Adherence and Persistence in Mexico Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the report entitled Improving
More informationPaying for Genomic Testing and Associated Care. Scott Ramsey, MD, PhD FRED HUTCHINSON CANCER RESEARCH CENTER
Paying for Genomic Testing and Associated Care Scott Ramsey, MD, PhD FRED HUTCHINSON CANCER RESEARCH CENTER Cost of Cancer Genome Sequencing Will vary with: Approach Whole genome, exome, transcriptome
More informationLeveraging Data for Targeted Patient Population Health Improvements
Leveraging Data for Targeted Patient Population Health Improvements Diabetes Impact on Health in America Diabetes is a major health concern in the United States today. The Centers for Disease Control
More informationRadiation Oncology. The conf ident path to treatment Philips Radiation Oncology Solutions
Radiation Oncology The conf ident path to treatment Philips Radiation Oncology Solutions The confident path to treatment Philips Radiation Oncology Solutions Imaging Image registration Contouring Treatment
More informationDriving Outcomes By Scaling Population Health Management
Driving Outcomes By Scaling Population Health Management Henry C. Chueh, MD, MS, FACMI March 3, 2016 Laboratory of Computer Science Massachusetts General Hospital Conflict of Interest Henry C. Chueh: Consultant
More informationMedicare & Medicaid EHR Incentive Programs
Medicare & Medicaid EHR Incentive Programs Stage 2 NPRM Overview Robert Anthony March 6, 2012 Proposed Rule Everything discussed in this presentation is part of a notice of proposed rulemaking (NPRM).
More informationGet the Right Reimbursement for High Risk Patients
Get the Right Reimbursement for High Risk Patients A Proven Strategy for Managing Hierarchical Condition Categories (HCC) in your EHR 847-272-1242 sales@e-imo.com e-imo.com 1 OVERVIEW Medicare Advantage
More informationSocial Determinants of Health
FORECAST HEALTH WHITE PAPER SERIES Social Determinants of Health And Predictive Modeling SOHAYLA PRUITT Director Product Management Health systems must devise new ways to adapt to an aggressively changing
More informationLeverage Healthcare Technology Applications to Improve Primary Nonadherence.
Leverage Healthcare Technology Applications to Improve Primary Nonadherence. Page 2 Medication adherence starts with assessing a patient s opportunity for having positive outcomes on a specific therapy.
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationSpending estimates from Cancer Care Spending
CALIFORNIA HEALTHCARE FOUNDATION August 2015 Estimating Cancer Care Spending in the California Medicare Population: Methodology Detail This paper describes in detail the methods used by Deborah Schrag,
More informationSurveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH
Surveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH Presentation Objectives Describe Future Role of Registries & Registrars Challenges to cancer surveillance
More informationPHARMO Database Network
Pros & cons in Oncology studies PHARMO Myrthe Database van Herk-Sukel, Network PhD 1 Disclosure Myrthe van Herk-Sukel is an employee of the PHARMO Institute for Drug Outcomes Research. This independent
More informationCare Management Technologies
Care Management Technologies Insight and Action in Behavioral Health Role of MH/DD SA Provider in Improving Care and Lowering Costs: Using Data to Demonstrate Your Value North Carolina Providers Council
More informationApril 2o14. The 2013 Drug Trend Report Highlights
April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced
More informationSolving for Type 2 Diabetes in the Workplace
TEXAS BUSINESS GROUP ON HEALTH Solving for Type 2 Diabetes in the Workplace Bharath Thankavel, MD Medical Director, Value Based Care Blue Cross and Blue Shield of Texas @BCBSTX Blue Cross and Blue Shield
More informationLessons Learned from Meaningful Use Implementation. Cynthia L. Bero, MPH Partners HealthCare May 19, 2011
Lessons Learned from Meaningful Use Implementation Cynthia L. Bero, MPH Partners HealthCare May 9, 20 Meaningful Use Plan of Action Learn the HITECH program Certified EHR Technology. Analyze gap between
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationThe Power and Promise of Digital Health
The Power and Promise of Digital Health Laurel Pickering, MPH EVP, Enterprise Solutions Welldoc, Inc. 2018 WellDoc, Inc. Intellectual Property. All rights reserved Agenda Problem are we trying to solve
More informationKen Buback, MA, CPCC (USA)
Ken Buback, MA, CPCC (USA) Brian Marsh, MBA, PCC (USA) Express Coaching: A Breakthrough Research Study on Improving the Health Status of Diabetic Patients 1 Agenda Overview of organization and managed
More informationEnriched RWE study in the Nordics a case study
Enriched RWE study in the Nordics a case study RWD conf. Helsinki, November 28, 2018 Susanne Kihlblom, MSc Pharm., Diplom.Clin.Trials Copyright 2017 IQVIA. All rights reserved. IQVIA 2017. All rights reserved.
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationSIM HIT Assessment. Table 1: Practice Capacity to Support Data Elements
SIM HIT Assessment This interactive document allows the Clinical Health Information Technology Advisors (CHITAs) to work with a SIM practice to institute sustainable quality improvement. The SIM HIT Assessment:
More informationImproving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia
July 2016 Improving Type 2 Diabetes Therapy Compliance and Persistence in the Kingdom of Saudi Arabia Appendix PATIENT ACTIVATION Introduction This Appendix document provides supporting material for the
More informationACO Congress Conference Pre Session Clinical Performance Measurement
ACO Congress Conference Pre Session Clinical Performance Measurement Lynne Rothney-Kozlak, MPH Interim VP, ACO Collaborative (Independent Consultant) October 25, 2010 Agenda for Presentation 1. The Framework
More informationSuccesses in Regional Collaboration to Achieve the Triple Aim Oregon. Pay for Performance Summit San Francisco March 24, 2014
Successes in Regional Collaboration to Achieve the Triple Aim Oregon Pay for Performance Summit San Francisco March 24, 2014 Agenda Oregon Health Care Quality Corporation (Q Corp) Background Priority Projects
More informationNot all NLP is Created Equal:
Not all NLP is Created Equal: CAC Technology Underpinnings that Drive Accuracy, Experience and Overall Revenue Performance Page 1 Performance Perspectives Health care financial leaders and health information
More informationPHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS
PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS For Producer Audience Only - Please Do Not Distribute Regence has selected Prime Therapeutics as the Pharmacy benefits manager for its health plans.
More informationMarket Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
More informationNovartis: tackling adherence. ESPACOMP, September, 2010
Novartis: tackling adherence ESPACOMP, September, 2010 Novartis is a world-leading healthcare company Leading market position One of 20 largest companies by market capitalization Among most respected companies
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationTHE GROWTH OF SPECIALTY PHARMACY
UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important
More informationThank you for joining today, please wait while others sign in.
Webinar Instructions Thank you for joining today, please wait while others sign in. The audio portion of this call will be heard through your computer speakers. Please make sure your speakers are on and
More informationIntegrating HIPAA Into Your Compliance Program
Integrating HIPAA Into Your Compliance Program Fifth Annual National Congress on Health Care Compliance February 7, 2002 Glenna S. Jackson Vice President Compliance, MedStar Health Diane H. Meyer Chief
More information9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance
Pharmacy Quality Measures: Action Steps for Improvement Financial Support Financial support was provided for this activity through an unrestricted grant from Health Mart Systems, Inc. Christine Jacobson
More informationNWCDC 2018 Pharmacy Analytics in Workers Comp
NWCDC 2018 Pharmacy Analytics in Workers Comp Cliff Belliveau VP Business Intelligence What is Visual Analytics? Transforming data into insights that tell a story 2 A little history Jacquard loom Punch
More informationJefferies Healthcare Conference June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements Some of the statements included in this presentation, particularly those regarding the commercialization and ongoing clinical development
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationBeyond AI: Bringing Emotional Intelligence to the Digital
Beyond AI: Bringing Emotional Intelligence to the Digital World Emotions influence every aspect of our lives how we live, work and play to the decisions we make We are surrounded by hyper-connected devices,
More informationCost-Motivated Treatment Changes in Medicare Part B:
Cost-Motivated Treatment Changes in Medicare Part B: Implications for Non- Medical Switching September 2016 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Medicare Part B: Implications for Non-Medical
More informationThree Rules for Measuring Physician Market Share
Crimson Market Advantage RESEARCH BRIEFING Three Rules for Measuring Physician Market Share Research and insights Performance Technologies Consulting and management Talent Development new definition Hospitals
More informationASO core offerings. Self-funded groups, sized 100+
ASO core offerings Self-funded groups, sized 100+ Regence BlueCross BlueShield of Oregon is an Independent Licensee of the Blue Cross and Blue Shield Association Regence ASO core offerings Under an ASO
More informationEHR Developer Code of Conduct Frequently Asked Questions
EHR Developer Code of Conduct Frequently Asked Questions General What is the purpose of the EHR Developer Code of Conduct? EHR Association (the Association) members have a long tradition of working with
More informationMonitoring the HCV care cascade to inform public health action
Monitoring the HCV care cascade to inform public health action Susan Hariri, PhD Division of Viral Hepatitis Centers for Disease Control and Prevention NASTAD Hepatitis Technical Assistance Meeting Washington
More informationApplying Six Sigma Principles to Drive Healthcare Behavior Change:
Applying Six Sigma Principles to Drive Healthcare Behavior Change: Using Medication Compliance to Improve Healthcare Outcomes Presented by: Todd Prewitt, Director of Clinical Operations/Medical Director,
More informationUnleashing Big Data in Oncology: Making Real World Cancer Data Useful
June 18, 2015 Unleashing Big Data in Oncology: Making Real World Cancer Data Useful Bobby Green, MD MSCE Vice President, Clinical Strategy Senior Medical Director bobby@flatiron.com www.flatiron.com Funding
More informationRisk Classification Modeling to Combat Opioid Abuse
Risk Classification Modeling to Combat Opioid Abuse Improve Data Sharing to Identify High-Risk Prescribers of Opioids Christopher Sterling Chief Statistician NCI, Inc. www.nciinc.com 11730 Plaza America
More informationCounty of Sacramento. Review of Population Health through Kaiser Permanente Data
County of Sacramento Review of Population Health through Kaiser Permanente Data Dr. Diane Dailey, M.D., Chief of Business Health Engagement Eileen Peterson, MPH, RD, TPMG Business Health Consultant, Public
More informationHow health plans can improve cancer care: from utilization management to delivery reform
Quality health plans & benefits Healthier living Financial well being Intelligent solutions How health plans can improve cancer care: from utilization management to delivery reform Michael Kolodziej, M.D.,
More informationIntroducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview
Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate
More informationThe Alabama Regional Extension Center
The Alabama Regional Extension Center Mission Statement The Alabama Regional Extension Center is part of the Center for Strategic Health Innovation (CSHI) in the College of Medicine at the University of
More informationPain Management Pathway Redesign. Briefing on Patient Journey Mapping approach to patient interviews
Pain Management Pathway Redesign Briefing on Patient Journey Mapping approach to patient interviews Purpose This proposal outlines the approach being undertaken to capture and report patient experience
More informationCONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management
CONFRONTING THE OPIOID EPIDEMIC 2 0 1 8 OPIOID ABUSE IS A CRISIS IN THE U.S. OptumRx Opioid Risk Management attacks this complex, deeply embedded problem with a comprehensive approach featuring five interrelated
More informationIntroducing DIA-TEC CLOUDTM. Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM
Introducing DIA-TEC CLOUDTM Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM Technology. Education. Community. Diabetes happens in real time. Now,
More informationCEO Operational Report. Annual General Meeting 23 October 2013
CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationLongitudinal Care Management. September 2016
Longitudinal Care Management September 2016 Risk Score Assignment of Longitudinal CM Other C M Referral sources Screening: Need CM? Clinical Assessment tools Program Services Integrated Care Management
More informationEstablishing a Framework to Evaluate Real-World Endpoints
Establishing a Framework to Evaluate Real-World Endpoints Introduction July 10, 2018 Washington, DC Advances in data analytics and data capture through electronic health records (EHRs) and medical/pharmacy
More informationImaging Performance Partnership. A Data Driven Approach to Your Imaging Program Strategy
Imaging Performance Partnership A Data Driven Approach to Your Imaging Program Strategy PROGRAM GOALS Imaging Performance Partnership has a wide array of tools to support various aspects of imaging business
More informationGetting started with Prime
Getting started with Prime How does a pharmacy plan work? When you visit your doctor, he or she may prescribe medicine for you. Here's how the plan works: Take your prescription and member ID card to the
More informationUnderstanding Your Patient Care Opportunity Report (PCOR)
Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient
More informationTelemedicine: Connecting Behavioral Health and Medical Care
Telemedicine: Connecting Behavioral Health and Medical Care Lawrence S. Brown, Jr., MD, MPH, FASAM CEO, START Treatment & Recovery Centers Clinical Associate Professor of Medicine and Health Care and Policy
More information- Description, Objectives, Operational Framework
2 1. CNCD - Overview (significance, causes, burden) 2. CDAP - Description, Objectives, Operational Framework 3. Research Findings of Study on CDAP - Research Objectives and Methodology - Limitations and
More information2015 Annual Convention
2015 Annual Convention Date: Tuesday, October 13, 2015 Time: 8:00 am 9:30 am Location: Gaylord National Harbor Resort and Convention Center, National Harbor 2 Title: Activity Type: Speaker: Benefit from
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationTools, Reports, and Resources
Tools, Reports, and Resources What the National Cancer Database (NCDB) does for CoC-Accredited Programs By using the NCDB, CoC-accredited programs can proactively improve delivery and quality of care for
More informationCMS-3311-P 100 TABLE 6: MEANINGFUL USES OBJECTIVES AND MEASURES FOR 2015 THROUGH 2017
CMS-3311-P 100 TABLE 6: MEANINGFUL USES OBJECTIVES AND MEASURES FOR 2015 THROUGH 2017 Provider Type Eligible Professional Proposed Objectives for 2015, 2016 and 2017 CPOE Prescribing Clinical Decision
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationInnovator Case Studies: Oncology Networks
Innovator Case Studies: Oncology Networks J. Ike Nicoll Chief Executive Officer Cancer Clinics of Excellence Alan Armer, Ph.D. Vice President, Research & Development Catholic Health Initiatives Cancer
More information